CRP and B-cell non-Hodgkin lymphoma: The number of treatment lines before CAR-T therapy and C-reactive protein (CRP) >30 mg/l at the time of lymphodepletion has been reported to associate with poor progression-free survival (PFS) in R/R aggressive B-cell lymphoma, and CRP >30 mg/L further associated with shorter OS (27).